Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Commercialization, R&D alliance with Biovail in cardiovascular area announced
June 6th, 2005
Kos Pharmaceuticals, Inc. (KOSP) announced that it has entered into a strategic commercialization and research and development alliance with Biovail Corporation (BVF) and certain of its subsidiaries in the area of cardiovascular disease. Pursuant to the agreements, Kos acquired Teveten (eprosartan mesylate), Teveten HCT (eprosartan mesylate/hydrochlorothiazide) and obtained exclusive sales and marketing rights to Cardizem LA (diltiazem hydrochloride) in the United States. These anti-hypertensive products are complementary to Kos' existing cholesterol franchise, offering an excellent opportunity to further leverage Kos' existing sales force. In...
Source: Biotech Business Week (2005-06-06)
|
